FDA approves IV Poteligeo for Treating Two Rare types of Cutaneous T cell lymphoma (CTCL)

 FDA approves IV Poteligeo for Treating Two Rare types of Cutaneous T cell lymphoma (CTCL)

FDA approves IV Poteligeo for Treating Two Rare types of Cutaneous T cell lymphoma (CTCL)

Shots:

  • FDA approves Kyowa Kirin’s Poteligeo drug for R/R Mycosis fungoides (MF) and Sézary syndrome (SS)
  • Poteligeo received Orphan Drug designation with addition permission granted on basis of Priority Review and Breakthrough Therapy
  • The approval is based on a clinical trial of 372 patients with MF or SS. Study reported mPFS (Poteligeo vs Vorinostat) is 7.6mos vs 3.1mos
Click here to read full press release/ article | Ref: US FDA | Image: BioNJ 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post